Home › NCT05024344

ESP Block vs Control for Pain Control Following Percutaneous Nephrolithotomy

Erector Spinae Plane Block Versus Control for Pain Control Following Percutaneous Nephrolithotomy: A Randomized, Double-Blind, Placebo Controlled Study

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adults, male and female greater than or equal to 18 years of age and undergoing non-emergent percutaneous nephrolithotomy Monday through Friday between the hours of 6:00AM and 4:00PM.
* Female participants of childbearing potential will be required to provide a negative pregnancy test.
* Ability to understand and teach back consent for the procedure.
* Willingness to sign consent for procedure.
* English speaking.

Exclusion Criteria:

* Emergent surgery status.
* Local infection
* Allergy to local anesthetics.
* Recreational drug use.
* Inability to provide informed consent.
* Pregnancy or breastfeeding.
* History of Guillain-Barre' Syndrome.
* Underlying medical conditions that would post a significant risk to the patient.
* Opioid use \>90 days in the year leading up to surgery.

About the study

The purpose of this study is to investigate the use of the erector spinae (ESP) block in reducing the morphine milligram equivalent (MME) consumption post percutaneous nephrolithotomy. Objectives:

1. \- Determine if there is a significant effect on post percutaneous nephrolithotomy MME consumption with the usage of an ESP block vs. saline control. 2. \- Determine if there is a significant effect on reported pain levels with the use of an ESP block vs. saline control in post percutaneous nephrolithotomies.

What is being tested

• Erector Spinae Plane Block (procedure)
• Ropivacaine 0.5% Injectable Solution (drug)
• Dexamethasone (drug)

Sponsor: University of Tennessee Medical Center · Participants: 128 · Started: Aug 9, 2021

Contact the study team

• Jason Buehler, MD · Phone: 865-305-9220
• Aimee Pehrson · Phone: 865-305-5432

Official record on ClinicalTrials.gov — NCT05024344

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.